Vaccine specialist Novavax (NVAX -0.78%) plans to file for an emergency use authorization with the Food and Drug Administration for its COVID-19 vaccine candidate in July. In addition, the biotech's vaccine candidate for influenza, NanoFlu, is waiting for a green light from the regulator. Last year, a phase 3 study of NanoFlu showed it to be superior to the market-leading flu vaccine from Sanofi (SNY 0.39%) in a head-to-head match-up.
This week, Novavax reported strong data from an animal study of a new inoculation that combines both of those promising vaccines.
The combo vaccine candidate was tested in hamsters and ferrets. Administered in a two-shot regimen, it produced a high level of antibodies against both flu and COVID-19 in the animals, comparable to the levels that were seen when either vaccine was tested alone. Significantly, hamsters who were immunized with the combo shot were challenged with SARS-CoV-2, and had no replicating coronavirus in their upper or lower respiratory tracts, nor did they have any signs of viral pneumonia.
"This study's results build on our success to-date with NVX-CoV2373, and with NanoFlu, which successfully achieved all of its objectives in a pivotal Phase 3 trial announced last year," Dr. Gregory M. Glenn, Novavax's president of research and development, said in a press release. "We believe that this novel combination vaccine candidate, which leverages Novavax' technology platform and Matrix-M adjuvant, could be an important future tool in the long-term fight against both of these harmful respiratory viruses."
Moderna (MRNA -0.93%) also plans to produce a combination vaccine, but so far is trailing Novavax in that effort. Novavax stock was down by 6.6% as of 2 p.m. EDT on Wednesday, while the S&P 500 was off by 1.7%.